BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
23.50
+0.46 (1.97%)
Nov 21, 2024, 12:44 PM EST - Market open
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $2.73M in the quarter ending September 30, 2024, a decrease of -33.22%. This brings the company's revenue in the last twelve months to $217.77M, up 2,209.77% year-over-year. In the year 2023, BridgeBio Pharma had annual revenue of $9.30M, down -88.02%.
Revenue (ttm)
$217.77M
Revenue Growth
+2,209.77%
P/S Ratio
19.29
Revenue / Employee
$391,664
Employees
556
Market Cap
4.44B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 8.22B |
ICU Medical | 2.34B |
Integer Holdings | 1.71B |
Alkermes | 1.51B |
Haemonetics | 1.36B |
Prestige Consumer Healthcare | 1.11B |
Ultragenyx Pharmaceutical | 522.75M |
Axsome Therapeutics | 338.46M |
BBIO News
- 1 day ago - BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Benzinga
- 3 days ago - Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months - GlobeNewsWire
- 3 days ago - BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - Business Wire
- 3 days ago - BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia - GlobeNewsWire
- 7 days ago - BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats - Seeking Alpha
- 16 days ago - BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management - GlobeNewsWire
- 22 days ago - BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire
- 4 weeks ago - BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - GlobeNewsWire